Objective: Pharmacological activation of adenosine signaling has been shown to increase b-cell proliferation and thereby b-cell regeneration in zebrafish and rodent models of diabetes. However, whether adenosine has an endogenous role in regulating b-cell proliferation is unknown. The objective of this study was to determine whether endogenous adenosine regulates b-cell proliferationdeither in the basal state or states of increased demand for insulindand to delineate the mechanisms involved.
INTRODUCTION
Type 1 and type 2 diabetes feature a shortage of functional b-cells [1] , resulting from b-cell death, insulin deficiency, or insulin resistance.
The current treatments used to counteract this insufficiency include transplantation of pancreas or pancreatic islets or administration of insulin or insulin sensitizers/secretagogues. However, there is a shortage of pancreas transplant donors, and glycemia is difficult to adequately control with pharmacological treatments in severe cases of diabetes. Alternative strategies, preferably curative ones, therefore, are needed. One potentially curative strategy would be to stimulate the remaining b-cells to proliferate. Depletion of b-cells in zebrafish and rodent models of diabetes is followed by significant recovery of the bcell mass, indicating that the pancreas has the capacity to regenerate [2e4] . Likewise, the human b-cell mass is known to adapt to the high demand for insulin that occurs in states such as pregnancy and obesity [5e7] . Identifying the signals that drive this pancreatic adaptability could potentially enable the development of a curative diabetes treatment based on increasing the number of functional b-cells.
As an adaptive response to the insulin resistance that prevails in pregnancy, which ensures that enough glucose reaches the fetus, the mother's b-cell mass expands [8, 9] , increasing the production of insulin and ensuring that the mother's blood glucose levels remains under control. Several pregnancy hormones, including prolactin and placental lactogen [10] , stimulate b-cell proliferation by inducing the downstream effectors FoxM1, Menin, osteoprotegerin, and serotonin [11e14] . As a result, insulin secretion increases in pregnancy. It is possible that positive feedback loops triggered by this high demand for insulin further potentiate b-cell proliferation. Moreover, because gestational diabetes is associated with an increased risk of developing type 2 diabetes later in life [15, 16] , the inverse action of the mechanisms underlying the failure of compensatory proliferation of b-cells in gestational diabetes may therefore have potential as novel interventions in the treatment of diabetes. Bridging developmental biology and drug discovery, we have previously used the zebrafish model to perform in vivo screening for drugs, promoters of b-cell regeneration in zebrafish, we found that the most potent 'hits' converged on agonism of the adenosine pathway and thereby promoted b-cell proliferation. These hits included the nonspecific adenosine receptor agonist NECA, the adenosine kinase (Adk) inhibitor A-134974, and phosphodiesterase inhibitors. Adk inhibitors increase the levels of endogenous adenosine by preventing the degradation of adenosine, i.e. the phosphorylation of adenosine to AMP. Adk inhibitors were independently found to increase b-cell proliferation in a different screen for b-cell proliferation in rat b-cells [17] . Still unknown is whether endogenously produced adenosine regulates b-cell proliferationdeither in the basal state or in states where there is a high demand for insulin. Here, we show that adenosine signaling through the A2a receptor is required for compensatory b-cell proliferation in mice during pregnancy and is sufficient to promote proliferation of mouse b-cells in vitro. Together, our work suggests that adenosine signaling has an important role in generating b-cell homeostasis, a feature that could be therapeutically exploited to increase the number of b-cells in people with diabetes.
RESULTS

Pharmacological activation of adenosine signaling promotes
b-cell proliferation independently of an apoptotic microenvironment Using zebrafish models of b-cell proliferation and regeneration, we previously identified adenosine signaling as a mitogen important in bcell proliferation during regeneration but not in b-cell proliferation during development [2] . We now sought to determine whether this differential effect is due to the apoptotic microenvironment that results from the ablation of b-cells or to the increased demand for insulin in venus-geminin), a system based on FUCCI (fluorescence ubiquitination cell cycle indicator) [18] . As expected, treating these transgenic zebrafish with the adenosine agonist NECA after ablation of their bcells significantly increased b-cell proliferation, whereas such treatment had only a modest effect on b-cell proliferation in the absence of b-cell ablation (Figure 1AeE ). However, when we used the same ablation system to target a different cell type, i.e. somatostatin-producing d-cells rather than insulin-producing b-cells, we found that Figure 1H ; for absolute numbers see Figure S1 ). Similar data were obtained when b-cell proliferation was analyzed after 1 or 2 days of regeneration (data not shown). Thus, we did not find any evidence for adenosine signaling being a more potent driver of b-cell proliferation in an apoptotic microenvironment.
2.2. Deletion of Adora2a in the pancreas has no effect on glucose regulation and b-cell proliferation in the basal state
We previously showed that knock-down of adora2aa, corresponding to the mammalian adenosine receptor Adora2a, abolished the ability of the non-specific adenosine agonist NECA to promote b-cell proliferation in zebrafish [2] . Therefore, we now sought to determine whether the A2a receptor has an endogenous role in regulating glucose levels and b-cell proliferation in mice. To do so, we deleted Adora2a in the whole pancreas by crossing a floxed allele of Adora2a with Pdx1-Cre (designated Adora2a f/f Pdx1cre ). This approach generated mice with a marked deficiency in Adora2a expression in islets but normal levels of Adora2a expression in the liver (Figure 2A) . A comparison between female Adora2a f/f Pdx1cre mutant and control mice did not show any significant differences in body weight ( Figure 2B ), blood glucose levels ( Figure 2C ), plasma insulin levels ( Figure 2D ), plasma glucagon levels To examine whether adenosine signaling has a role in the homeostatic control of glycemia and b-cell proliferation when the demand for insulin is high, we studied pregnant Adora2a f/f Pdx1cre mutant mice at gestational day 13.5 (G13.5), a time at which the compensatory b-cell proliferation associated with pregnancy is at its peak [11] . We found that pregnant Adora2a f/f Pdx1cre mutant mice had significantly higher levels of glucose in their blood than pregnant control mice ( Figure 3A) , despite having comparable levels of insulin ( Figure 3B ), and significantly lower levels of glucagon ( Figure 3C ). That the Adora2a f/f Pdx1cre (Figure 4DeF) . Together, these data suggest that adenosine signaling through A2a has a direct effect on b-cells, an effect necessary for stimulating b-cell proliferation and maintaining a normal basal level of b-cell proliferation in islets grown in vitro.
We next examined whether pharmacological agonism of the A2a receptor is sufficient to induce b-cell proliferation. We compared the effects of the non-specific agonist NECA, which activates all four of the mammalian adenosine receptors, and those of the A2a-specific agonist UK432097 on b-cell proliferation in islets isolated from wild- type mice. UK432097 potently increased b-cell proliferation, whereas NECA did not increase b-cell proliferation to the same extent (Figure 4GeJ ). These results suggest that an increase in b-cell proliferation is better achieved by stimulating specifically the A2a receptor, rather than all adenosine receptors.
DISCUSSION
In this study, we uncover a critical role for adenosine signaling in regulating b-cell homeostasis. By studying b-cell regeneration in zebrafish, compensatory b-cell proliferation in pregnant mice, and bcell proliferation in cultured mouse islets, we show that both exogenous adenosine receptor agonists and endogenous adenosine signal via the A2a receptor to regulate b-cell homeostasis. These findings pave the way for the development of A2a-activating drugs that can increase b-cell proliferation. While others found that ATP regulates homeostasis of b-cell proliferation [19] , we show that adenosine signaling is important for both bcell regeneration [2] and compensatory b-cell proliferation (this study). ATP is known to regulate the b-cell mass through effects on b-cell polarization; glucose catabolism increases intracellular ATP levels, which leads to closure of K-ATP channels and depolarization of b-cells, and hence to an increase in b-cell proliferation [19] . It is possible that ATP and adenosine work in concert in regulating homeostasis of the bcell mass. Indeed, because ATP degrades to form adenosine, adenosine may in fact mediate part of the effect attributed to ATP, because ATP is co-secreted with insulin and degrades to form adenosine.
We show that adenosine has only a minor role in regulating b-cell proliferation under basal conditions but a major one in regulating the b-cell proliferation when there is great demand for insulin secretion (which is coupled to ATP secretion and hence adenosine production), such as during pregnancy in mice or b-cell depletion in zebrafish. Our finding that basal b-cell proliferation is dependent on A2a-adenosine signaling in cultured islets (which have no insulin resistance or b- Mammals have four adenosine receptors, A1, A2a, A2b, and A3. A1 and A3 couple primarily to Gai and thus decrease intra-cellular levels of cAMP, whereas A2a and A2b couple primarily to Gas and thus increase levels of cAMP. Zebrafish, however, have twelve adenosine receptors as a result of genomic duplications. Through in vitro studies with an A2a-specific agonist and in vivo studies with mice lacking A2a in their pancreas or b-cells, we found that it is the A2a receptor that mediates b-cell proliferation in response to adenosine signaling.
Furthermore, we show that A2a-specific agonists have a stronger effect on mouse b-cell proliferation than NECA, perhaps because NECA also activates the A1 and A3 receptors, which, in turn, activate Gai and thereby counteract the downstream effects of A2a signaling (which is mediated by Gas). This explanation is also consistent with findings showing that adenosine signaling is affected by phosphodiesterases (which degrade cAMP) and how adenosine promotes the basal level of b-cell proliferation in vitro [2, 21, 22] . Moreover, NECA was recently shown to increase human b-cell proliferation [24] ; it would be interesting to examine whether A2a-specific agonists are more potent than non-specific adenosine agonists in increasing b-cell proliferation in human islets grown in vitro or transplanted to immunodeficient mice.
Knowing which receptor mediates adenosine's effects on b-cell regeneration and proliferation in mammalian models is critical for potential future therapeutic development. Adk inhibitors increase the levels of endogenous adenosine by preventing the degradation of adenosine, i.e. the phosphorylation of adenosine to AMP. Recent findings suggest that the adenosine pathway might also be important for glucose control in humans. Intriguingly, 9 of 11 individuals with homozygous null mutations in ADK have recurrent hypoglycemia [25] , some already at birthda finding that may reflect an increase in b-cell proliferation and b-cell mass in these individuals. ADK serves to degrade adenosine; indeed, several of these individuals with homozygous null mutations in ADK have abnormally high levels of adenosine in their urine, most likely reflecting a similar increase in levels of adenosine in their blood. Moreover, a similar link was reported in a child with hypoglycemia: an association between an activating mutation in glucokinase (which increases ATP and hence adenosine levels) and the presence of hypoglycemia, unusually large islets and b-cell proliferation [26] . Together with our findings, these observations suggest that adenosine is central to b-cell homeostasis and glucose control, as it is in zebrafish and mice.
b-cell regeneration, as well as compensatory increases in b-cell number, can occur through different mechanismsde.g. proliferation [27] , neogenesis [28] , and reprogramming [4] . In this regard, our previous unbiased screens have identified enhancers of b-cell regeneration through different mechanisms; e.g. adenosine signaling promotes bcell regeneration via increasing b-cell proliferation [2] , whereas IGFBP1 promotes b-cell regeneration via increasing a-to-b-cell transdifferentiation [29] . Together, this line of research highlights the importance of performing unbiased screens for identification of potent endogenous pathways and mechanisms that can increase the number of b-cells, as well as translating initial phenotypic findings in discovery models to functional outcomes in mice and ultimately humans.
MATERIALS AND METHODS
Zebrafish experiments
All studies involving zebrafish were performed in accordance with local guidelines and regulations and approved by Stockholms djurförsök-setiska nämnd. The following previously published transgenic zebrafish lines were used:
[2], Tg(sst2:NTR,cryaa:Cerulean) KI102 [29] and Tg(ins:Venus-zGeminin; cryaa:Venus) KI107 [29] . We ablated b-or d-cells in Tg(ins:Flag-NTR) or Tg(sst:NTR) zebrafish larvae by incubating the larvae in E3 supplemented with 10 mM metronidazole (MTZ; SigmaeAldrich), 1% DMSO (VWR), and 0.2 mM 1-phenyl-2-thiourea (PTU; Acros Organics) from 3 to 4 days post fertilization (dpf).
Fluorescent imaging of zebrafish larvae
Fluorescent imaging was performed according to standard procedures and analyzed with a Leica SP8 confocal microscope. The whole endocrine portion of the pancreas was scanned in all larvae analyzed.
Confocal stacks were analyzed with ImageJ software. b-Cell proliferation was assessed by counting the number of b-cells marked by Tg(ins:venus-geminin).
Mouse experiments
All studies involving mice were performed in accordance with local guidelines and regulations and approved by Stockholms djurförsök-setiska nämnd. To delete Adora2a in the pancreas (thus generating mutant mice termed Adora2a f/f Pdx1cre ), we crossed Adora2a tmDyj mice (Jackson Laboratory) [30] with mice carrying cre-recombinase under the control of the mouse Pdx1 promoter (Tg(Pdx1-cre)89.1Dam/ Mmucd) mice [31] . To delete Adora2a specifically in the b-cells of mice (thus generating Adora2a f/f MIPcre mice), we crossed Adora2a tmDyj mice with mice carrying cre-recombinase under the control of the mouse insulin promoter (B6.Cg-Tg(Ins1-cre/ERT)1Lphi/J) [32] . Adora2a f/f from respective breeds was used as control mice, i.e. mice that do not carry cre-recombinase but in which both Adora2a alleles are floxed. Ideally, one should also examine mice carrying only the Cre lines as independent controls. However, we find that deletion of Adora2a has the same effect on basal b-cell proliferation in cultured islets from two different Cre lines, suggesting that the Adora2a-mutant phenotype we see is not an artefact arising from the integration of Cre. Genotyping of mice was done by PCR using the following primers: Adora2a, forward primer 5 0 -GGGCAAGATGGGAGTCATT-3 0 , reverse primer 5 0 -ATTCTGCATCTCCCGAAACC-3 0 ; and cre forward primer 5 0 -GCG GTC TGG CAG TAA AAA CTA TC-3 0 , reverse primer 5 0 -GTG AAA CAG CAT TGC TGT CAC TT-3 0 . To activate the cre-recombinase in Adora2a f/f MIPcre mice, we gave them an oral gavage of 100 ml of 20 mg/ml tamoxifen (T5648, SigmaeAldrich) once per day for 5 days; control Adora2a f/f mice were treated in the same way. The tamoxifen was dissolved in 10% v/v ethanol and 90% v/v corn oil. Recombination efficiency was assessed by crossing Tg(Ins1-cre/ ERT)1Lphi/J) with a transgenic reporter mouse Tg(Rosa-CAG-LSLtdTomato-WPRE) that expresses Tomato after recombination [33] ): recombination occurred in 78% of b-cells (as analyzed in 3 independent mice). For analysis of the effects of pregnancy on the pancreas, pregnant mice were euthanized on day 13.5 of pregnancy. Mice were housed in standardized cages with ad libitum access to standard diet and water, and with a 12-hour dayenight cycle. FreeStyle lite (Abbott) was used for monitoring blood-glucose values.
Glucose and insulin tolerance tests
To analyze glucose tolerance, we fasted mice overnight and then gave them 2 g glucose/kg bodyweight (49163, BioUltra glucose solution, SigmaeAldrich) via oral gavage. Blood parameters were measured directly before the administration of glucose, as well as at 7.5, 15, 30, 60, and 120 min after the administration of glucose. To study insulin tolerance, we gave mice 1 IU insulin/kg body weight (Actrapid penfill insulin, Novo Nordisk) by intraperitoneal injection and measured bloodglucose levels before and 7.5, 15, 30 and 60 min after the insulin injection.
Measurement of plasma parameters
Blood samples were collected in EDTA-coated tubes (microvette, 16.444.100, Sarstedt) centrifuged for 10 min at 12,000 rpm, and the plasma supernatants were then collected for analysis. Enzyme-linked immunosorbent assays (ELISA) were used for determining insulin (#90080, Ultra-Sensitive Mouse ELISA Kit, Crystal Chem) and glucagon levels (10128101, Mercodia).
Isolating and in vitro culturing mouse islets
Wild-type C57Bl/6J mice (11e15 weeks old), Adora2a f/f , Adora2a f/f Pdx1cre and Adora2a f/f MIPcre mice fed a standard diet were euthanized by cervical dislocation. Collagenase P (Roche), at 0.3 mg/ml in Hank's buffered salt solution, was injected into the common bile duct such that it was distributed to the whole pancreas. The collagenase-expanded pancreas was dissected out and digested in a collagenase P-containing solution for 10 min in a 37 C water bath. After several washes, the islets were handpicked and incubated in RPMI 1640 media (Gibco) supplemented with 10% FBS (Gibco), 1% penicillin-streptomycin (Gibco), and 1% L-glutamine (Gibco) for 22 h at 37 C in 5% CO 2 TATA-box binding protein (Tbp; used in Figure 2A ), Beta-2 microglobulin (B2m) and beta-actin (Actb) were processed as endogenous control genes. Data analysis was done as described previously [34] ( Table 1 ). 
